Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIFC1 | Q9BW19 | 8/20 | 0.60 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30497131 | 1.00 | KIFC1 (0.60) | KIFC1S1PR1L3MBTL1DRD3HDAC1 | |
| SCHEMBL30497188 | 0.89 | KIFC1 (0.59) | KIFC1S1PR1L3MBTL1DRD3PLK1 | |
| SCHEMBL25249127 | 0.89 | KIFC1 (0.59) | KIFC1S1PR1L3MBTL1DRD3PLK1 | |
| SCHEMBL25253854 | 0.88 | KIFC1 (0.61) | KIFC1S1PR1L3MBTL1DRD3MAPT | |
| SCHEMBL30497171 | 0.88 | KIFC1 (0.61) | KIFC1S1PR1L3MBTL1DRD3MAPT | |
| SCHEMBL2227112 | 0.83 | HDAC4 (0.60) | HDAC1HDAC6 | |
| SCHEMBL8820950 | 0.83 | S1PR1 (0.54) | KIFC1S1PR1L3MBTL1HDAC1HDAC6 | |
| SCHEMBL25295021 | 0.82 | FABP4 (0.50) | KIFC1PLK1MAPK14 | |
| SCHEMBL30497244 | 0.82 | FABP4 (0.50) | KIFC1PLK1MAPK14 | |
| SCHEMBL30497248 | 0.81 | KIFC1 (0.66) | KIFC1L3MBTL1DRD3MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577537-A1 | SUBSTITUTED BICYCLES AS HSET INHIBITORS | Merck Patent GmbH (DE) | 2025-07-02 | — | — | EP | disclosed |
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2025-03-13 | — | — | US | disclosed |
| EP-4463444-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | Merck Patent GmbH (DE) | 2024-11-20 | — | — | EP | disclosed |
| WO-2024099898-A1 | SUBSTITUTED BI-AND TRICYCLIC HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024042007-A1 | SUBSTITUTED BICYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023131690-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | VHL, CDKN1A, CCNI | KIFC1 3173/4885S1PR1 1941/4885L3MBTL1 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.